Skip to Main content Skip to Navigation
Preprints, Working Papers, ...

Death receptors as targets in cancer

Abstract : Anti-tumour therapies based on the use PARAs (pro-apoptotic receptor agonists), including TRAIL (TNF-Related Apoptosis inducing Ligand) or monoclonal antibodies targeting TRAIL-R1 or TRAIL-R2, have been disappointing so far, despite clear evidence of clinical activity and lack of adverse events for the vast majority of these compounds, whether combined or not with conventional or targeted anti-cancer therapies. This brief review aims at discussing the possible reasons for the lack of apparent success of these therapeutic approaches and at providing hints in order to rationally design optimal protocols based on our current understanding of TRAIL signalling regulation or resistance for future clinical trials.
Document type :
Preprints, Working Papers, ...
Complete list of metadata
Contributor : Olivier Micheau Connect in order to contact the contributor
Submitted on : Thursday, May 1, 2014 - 7:00:03 AM
Last modification on : Sunday, June 26, 2022 - 1:53:02 AM
Long-term archiving on: : Thursday, July 31, 2014 - 10:35:51 AM


Files produced by the author(s)


  • HAL Id : inserm-00823459, version 1


Olivier Micheau, Sarah Shirley, Florent Dufour. Death receptors as targets in cancer. 2014. ⟨inserm-00823459⟩



Record views


Files downloads